Arima Genomics Publishes Study Supporting Aventa Lymphoma Test

Arima Genomics, Inc. has announced the publication of a significant research study that underscores the effectiveness of the Aventa™ Lymphoma test. This study, conducted in collaboration with the University of Michigan and New York University (NYU), highlights the test’s capability to identify genomic rearrangements relevant to diagnosis, prognosis, and potential therapeutic strategies.

The findings, released on February 26, 2026, bolster the importance of utilizing whole-genome sequence and structural information in providing insights for cancer therapy selection. The research specifically focuses on the analysis of routine formalin-fixed, paraffin-embedded (FFPE) pathology specimens, which are commonly used in clinical settings.

Advancing Cancer Diagnostics with Aventa Lymphoma

The Aventa Lymphoma test employs a whole-genome rearrangement detection approach, which Arima Genomics believes can enhance the diagnostic process for lymphoma patients. By detecting specific genomic alterations, the test aims to provide clinicians with crucial information that can guide treatment decisions and improve patient outcomes.

The collaboration with esteemed institutions like the University of Michigan and NYU reflects a commitment to advancing cancer research and diagnostics. The study’s publication in a peer-reviewed journal adds credibility to the findings, which could influence future clinical practices.

Arima’s Chief Executive Officer, Dr. Shankar V. Ramaswamy, emphasized the significance of this research, stating that it validates their efforts to integrate genomic insights into routine diagnostics. He noted, “The ability to detect genomic rearrangements in FFPE specimens opens new avenues for tailored therapy in lymphoma patients.”

Implications for Future Cancer Therapies

The implications of this research extend beyond diagnostics. By identifying rearrangements that may inform treatment decisions, the Aventa Lymphoma test has the potential to enhance therapeutic strategies for lymphoma patients. This aligns with a growing trend in oncology toward personalized medicine, where treatments are tailored to the individual characteristics of each patient’s cancer.

As the field of genomics continues to evolve, Arima Genomics is poised to play a pivotal role in shaping the future of cancer therapy selection. The company’s commitment to rigorous research and collaboration with leading academic institutions positions it to make significant strides in cancer diagnostics.

In conclusion, the publication of this study marks a notable advancement in the field of lymphoma diagnosis and treatment. With the support of rigorous academic research, the Aventa Lymphoma test could reshape how clinicians approach cancer therapy, ultimately improving outcomes for patients facing lymphoma.